Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AIM ImmunoTech Inc. stock logo
AIM
AIM ImmunoTech
$0.09
-22.3%
$0.09
$0.06
$0.45
$6.61M0.76574,685 shs2.31 million shs
Avalon GloboCare Corp. stock logo
ALBT
Avalon GloboCare
$3.00
-4.8%
$3.64
$2.11
$12.60
$5.68M0.03475,628 shs14,461 shs
Neuralstem, Inc. stock logo
CUR
Neuralstem
$0.64
-7.2%
$1.06
$1.10
$13.78
$1.34M1.81236,278 shs307,969 shs
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
$0.31
-7.3%
$0.22
$0.10
$1.37
$13.75M1.21.57 million shs230,310 shs
2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AIM ImmunoTech Inc. stock logo
AIM
AIM ImmunoTech
0.00%0.00%0.00%-23.83%-79.64%
Avalon GloboCare Corp. stock logo
ALBT
Avalon GloboCare
0.00%-8.70%-15.32%-35.58%-53.37%
Neuralstem, Inc. stock logo
CUR
Neuralstem
0.00%-8.12%-5.88%-35.99%-86.20%
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
0.00%-2.94%-5.66%+141.23%-75.56%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AIM ImmunoTech Inc. stock logo
AIM
AIM ImmunoTech
2.0484 of 5 stars
3.50.00.00.01.71.70.6
Avalon GloboCare Corp. stock logo
ALBT
Avalon GloboCare
2.2477 of 5 stars
0.05.00.04.33.01.70.0
Neuralstem, Inc. stock logo
CUR
Neuralstem
N/AN/AN/AN/AN/AN/AN/AN/A
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
0.8124 of 5 stars
0.05.00.00.00.62.50.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AIM ImmunoTech Inc. stock logo
AIM
AIM ImmunoTech
3.00
Buy$2.752,908.75% Upside
Avalon GloboCare Corp. stock logo
ALBT
Avalon GloboCare
0.00
N/AN/AN/A
Neuralstem, Inc. stock logo
CUR
Neuralstem
0.00
N/AN/AN/A
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AIM ImmunoTech Inc. stock logo
AIM
AIM ImmunoTech
$170K38.87N/AN/A$0.20 per share0.46
Avalon GloboCare Corp. stock logo
ALBT
Avalon GloboCare
$1.37M4.15N/AN/A($17.22) per share-0.17
Neuralstem, Inc. stock logo
CUR
Neuralstem
$260K5.17N/AN/A$6.64 per share0.10
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
$80K171.87N/AN/A($2.68) per share-0.11
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AIM ImmunoTech Inc. stock logo
AIM
AIM ImmunoTech
-$28.96M-$0.31N/AN/AN/A-12,594.21%-421.73%-147.54%N/A
Avalon GloboCare Corp. stock logo
ALBT
Avalon GloboCare
-$16.71M-$19.96N/AN/A-1,125.59%N/A-73.69%8/18/2025 (Estimated)
Neuralstem, Inc. stock logo
CUR
Neuralstem
-$4.93MN/A0.00N/A-39,417.64%-170.51%-110.16%N/A
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
-$82.94M-$2.45N/AN/AN/AN/A-479.36%N/A

Latest CUR, AIM, ALBT, and NKGN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/13/2025Q1 2025
Avalon GloboCare Corp. stock logo
ALBT
Avalon GloboCare
N/A-$1.43N/A-$1.43N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AIM ImmunoTech Inc. stock logo
AIM
AIM ImmunoTech
N/AN/AN/AN/AN/A
Avalon GloboCare Corp. stock logo
ALBT
Avalon GloboCare
N/AN/AN/AN/AN/A
Neuralstem, Inc. stock logo
CUR
Neuralstem
N/AN/AN/AN/AN/A
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AIM ImmunoTech Inc. stock logo
AIM
AIM ImmunoTech
0.05
0.75
0.75
Avalon GloboCare Corp. stock logo
ALBT
Avalon GloboCare
N/A
0.11
0.11
Neuralstem, Inc. stock logo
CUR
Neuralstem
N/A
2.53
2.53
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
N/A
0.02
0.02

Institutional Ownership

CompanyInstitutional Ownership
AIM ImmunoTech Inc. stock logo
AIM
AIM ImmunoTech
12.02%
Avalon GloboCare Corp. stock logo
ALBT
Avalon GloboCare
1.42%
Neuralstem, Inc. stock logo
CUR
Neuralstem
38.30%
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
76.17%

Insider Ownership

CompanyInsider Ownership
AIM ImmunoTech Inc. stock logo
AIM
AIM ImmunoTech
0.02%
Avalon GloboCare Corp. stock logo
ALBT
Avalon GloboCare
37.30%
Neuralstem, Inc. stock logo
CUR
Neuralstem
5.38%
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
10.36%
CompanyEmployeesShares OutstandingFree FloatOptionable
AIM ImmunoTech Inc. stock logo
AIM
AIM ImmunoTech
2072.29 million68.74 millionNot Optionable
Avalon GloboCare Corp. stock logo
ALBT
Avalon GloboCare
51.89 million686,000Not Optionable
Neuralstem, Inc. stock logo
CUR
Neuralstem
62.10 millionN/ANot Optionable
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
N/A44.95 million40.29 millionNot Optionable

Recent News About These Companies

NKGen Biotech Chairman & CEO Paul Y. Song, M.D.
NKGen Biotech presents data from Phase 1/2a trial of troculeucel
NKGen Biotech announces administration of first dose of troculeucel
NKGen administers first troculeucel dose under compassionate use program

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
AIM ImmunoTech stock logo

AIM ImmunoTech NYSE:AIM

$0.09 -0.03 (-22.34%)
As of 04/4/2025
This is a fair market value price provided by Polygon.io. Learn more.

AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat human papilloma viruses, and genital warts, a sexually transmitted disease. AIM ImmunoTech Inc. has agreements with Amarex Clinical Research LLC; University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente; Jubilant HollisterStier; Sterling Pharma Solutions; Erasmus University Medical Center Rotterdam; Azenova, LLC; and Alcami Corporation. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.

Avalon GloboCare stock logo

Avalon GloboCare NASDAQ:ALBT

$3.00 -0.15 (-4.76%)
Closing price 03:59 PM Eastern
Extended Trading
$3.08 +0.08 (+2.67%)
As of 04:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and China. The company develops and delivers transformative cellular therapeutics, precision diagnostics, and clinical laboratory services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells. It is also developing mRNA-based Flash-CAR cell therapy platform. In addition, the company develops Avalon clinical-grade tissue-specific exosome (ACTEX); AVA-Trap, a therapeutic program provides an effective therapeutic option to combat COVID-19 and other life-threatening conditions involving cytokine storms; offers therapeutic and diagnostic targets utilizing QTY-code protein design technology with Massachusetts Institute of Technology (MIT), including using the QTY code protein design technology for development of a hemofiltration device to treat Cytokine Storm; and provides co-development of next generation, transposon-based, multi-target CAR-T, CAR-NK, and other immune effector cell therapeutic modalities with Arbele Limited. Avalon GloboCare Corp. has strategic partnership with HydroPeptide, LLC to engage in co-development and commercialization of a series of clinical-grade, exosome-based cosmeceutical, and orthopedic products; and corporate research agreement with the University of Pittsburgh of the Commonwealth System of Higher Education. The company was founded in 2016 and is headquartered in Freehold, New Jersey.

Neuralstem stock logo

Neuralstem NASDAQ:CUR

Neuralstem, Inc., a clinical stage biopharmaceutical company, focuses on the research and development of nervous system therapies based on its proprietary human neuronal stem cells and small molecule compounds. The company's stem cell based technology enables the isolation and expansion of human neural stem cells from various areas of the developing human brain and spinal cord enabling the generation of physiologically relevant human neurons of various types. Its lead product candidate is NSI-189, a chemical entity, which has been completed Phase II clinical trial for the treatment of major depressive disorder, as well as is in preclinical study for the treatment-refractory depression, Angelman Syndrome, Alzheimer's disease, ischemic stroke, diabetic neuropathy, irradiation-induced cognitive deficit, and long-term potentiation enhancement. The company also develops NSI-566, which has completed Phase II clinical trial for treating amyotrophic lateral sclerosis disease; Phase II clinical trial for the treatment of chronic ischemic stroke; and Phase I clinical trials for the treatment of chronic spinal cord injury, as well as is in preclinical study for the traumatic brain injury. In addition, it develops NSI-532, which is in preclinical study for treatment of Alzheimer's disease; and NSI-777 that is in preclinical study for treatment of human demyelinating diseases. Neuralstem, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.

NKGen Biotech stock logo

NKGen Biotech NYSE:NKGN

$0.31 -0.02 (-7.30%)
As of 03:26 PM Eastern

NKGen Biotech, Inc. operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. It develops SNK01, an autologous NK cell therapy; and SNK02, an allogeneic NK cell therapy, which are in Phase 1 clinical trials. The company was founded in 2017 and is based in Santa Ana, California.